Last update 20 Mar 2025

TUM-012

Overview

Basic Info

Drug Type
Chemical drugs
Synonyms
N-(methoxypolyethylene glycol 5000 carbamoyl)-1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanolamine
+ [3]
Target-
Action-
Mechanism-
Therapeutic Areas
Cardiovascular DiseasesOther Diseases
Active Indication
Reperfusion InjuryTransplant complicationOxygen radical damage
Inactive Indication-
Originator Organization
I-Coat Co. LLCI-Coat Co. LLC
Active Organization
iCoat Medical ABiCoat Medical ABStartup
Inactive Organization-
Drug Highest PhasePhase 2/3
First Approval Date-
RegulationOrphan Drug (European Union)
Login to view timeline

Related

2
Clinical Trials associated with TUM-012
NCT06582485
/ Not yet recruitingPhase 2/3
A Randomized, Placebo-controlled, Double-blind Phase 2b Trial to Assess the Efficacy and Safety of Ex Vivo Allograft Admin of ICM012 Solution 2 Mg/mL to Improve Allograft Function in Recipients of Donation After Circulatory Death Kidneys
NCT05246618
/ CompletedPhase 1/2
Phase I FIH Phase I/IIa Randomized Placebocontrolled Doubleblind Trial Evaluating Safety and Tolerability of ExVivo Deceased Donor Kidney Allograft Treatment With TUM012 to Minimize Ischemic Reperfusion Injury After Kidney Transplantation
100 Clinical Results associated with TUM-012
Login to view more data
100 Translational Medicine associated with TUM-012
Login to view more data
100 Patents (Medical) associated with TUM-012
Login to view more data
100 Deals associated with TUM-012
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Reperfusion InjuryPhase 3-
iCoat Medical ABiCoat Medical ABStartup
01 Jan 2025
Transplant complicationPhase 3-
iCoat Medical ABiCoat Medical ABStartup
01 Jan 2025
Oxygen radical damagePhase 2
Sweden
iCoat Medical ABiCoat Medical ABStartup
31 Mar 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT05246618 (ATMIRe, Corporate Publications)
ManualManual
Phase 1
Renal transplant rejection
18
(hzbqqzvemh) = Adverse events were equally distributed between the two treatment groups. There were no serious adverse events related to iCM012 treatment. hmwhccoelw (cjyusjegsv )
Met
Positive
19 Sep 2023
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free